Cerebriu A/SAktiv
Økonomiske nøgletal
Nøgletal
2025/26Balancens sammensætning
Selskabsskat
indkomstår 2024Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2019–2026
| 2018/19 | 2019/20 | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 | 2025/26 | |
|---|---|---|---|---|---|---|---|---|
| Balance — aktiver | ||||||||
| Likvide beholdninger | 721.740 | 2.463.047 | 8.804.805 | 6.097.591 | 26.584.580 | 8.264.756 | 42.914.822 | 68.144.492 |
| Omsætningsaktiver i alt | 1.148.109 | 3.802.594 | 12.194.585 | 11.383.318 | 31.553.488 | 17.867.785 | 50.067.670 | 75.843.700 |
| Anlægsaktiver i alt | 1.587.177 | 6.248.238 | 12.075.376 | 21.396.806 | 33.296.473 | 56.707.047 | 86.427.016 | 100.234.315 |
| Aktiver i alt | 2.735.286 | 10.050.832 | 24.269.961 | 32.780.124 | 64.849.961 | 74.574.832 | 136.494.686 | 176.078.015 |
| Balance — passiver | ||||||||
| Kortfristede gældsforpligtelser | 215.037 | 2.019.212 | 6.731.507 | 10.609.040 | 14.665.056 | 21.504.533 | 21.612.776 | 22.689.362 |
| Langfristede gældsforpligtelser | — | 3.418.133 | 9.166.999 | 13.040.714 | 8.554.071 | 8.399.126 | 9.127.027 | 10.402.375 |
| Gældsforpligtelser i alt | 215.037 | 5.437.345 | 15.898.506 | 23.649.754 | 23.219.127 | 29.903.659 | 30.739.803 | 33.091.737 |
| Selskabskapital | 621.399 | 732.510 | 839.872 | 882.594 | 1.577.813 | 1.804.438 | 3.108.620 | 4.106.517 |
| Overført resultat | 803.596 | -1.700.625 | -3.616.639 | -11.193.698 | 13.658.661 | -3.090.188 | 40.659.726 | 60.847.539 |
| Årets resultat | -368.700 | -1.728.628 | -3.677.944 | -4.090.429 | -6.483.189 | -12.678.902 | -20.190.326 | -31.436.305 |
| Egenkapital i alt | 2.359.100 | 3.630.473 | 6.504.067 | 6.228.638 | 41.148.119 | 42.695.410 | 104.381.594 | 142.798.125 |
| Resultatopgørelse | ||||||||
| Bruttofortjeneste | -425.906 | -1.076.593 | -1.316.333 | -1.889.181 | 3.583.313 | 6.342.638 | -401.101 | 2.995.319 |
| Resultat af primær drift | -470.380 | -1.695.687 | -3.586.654 | -4.338.992 | -10.359.954 | -15.832.327 | -25.715.938 | -24.892.557 |
| EBITDA | -437.047 | -1.635.626 | -3.515.460 | -4.216.430 | -10.243.628 | -15.740.405 | -23.623.698 | -20.350.785 |
| Resultat før skat | -471.016 | -1.913.964 | -4.114.203 | -5.035.361 | -11.545.564 | -16.723.696 | -26.376.419 | -37.425.651 |
| Årets resultat | -368.700 | -1.728.628 | -3.677.944 | -4.090.429 | -6.483.189 | -12.678.902 | -20.190.326 | -31.436.305 |
| Personaleomkostninger | 11.141 | 559.033 | 2.199.127 | 2.327.249 | 13.826.941 | 22.083.043 | 23.222.597 | 23.346.104 |
| Af- og nedskrivninger | 33.333 | 60.061 | 71.194 | 122.562 | 116.326 | 91.922 | 2.092.240 | 4.541.772 |
| Andre nøgletal | ||||||||
| Ansatte | — | 8 | 12 | 18 | 18 | 27 | 27 | 28 |
| Udbytte | 0 | 0 | 0 | 0 | — | — | — | — |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2026Cerebriu A/S's primary activities is to operate in the research and development, service, and sale of technology-based products in the healthcare sector, including activities related to enhancing radiological productivity, efficiency, workflow and quality through integration and automated brain imaging.
Development in activities and financesThe Company’s financial performance in the financial year amounted to a loss of DKK -31,436 thousand in line with budget. The equity at the balance sheet date amounted to DKK 142,798 thousand compared to DKK 104,382thousand in the previous financial year. Management considers the Company's financial performance satisfactory and in line with the budget and strategic directions. During the financial year, the Company succeeded in raising financing from existing and new investors. The financing covers capital requirements for development and operation during the next financial year. Based on this, it is Management’s assessment that the Company’s Annual Report may be presented under the going concern assumption. The Company expects to further intensify and expand its activities and organization especially within Sales and Marketing, but also in Research and Development.
Uddrag af ledelsesberetningen i den seneste årsrapport.